Cumberland Pharmaceuticals INC 8-K filings

Cumberland Pharmaceuticals has initiated an at-the-market offering program to sell up to $5.8 million of its common stock.

Cumberland Pharmaceuticals announced its 2023 financial results, reporting $40 million in revenue and $6 million in cash from operations, while also highlighting the expansion of its Caldolor product's FDA approval to include infants.